We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ECG:NYSEEverus Construction Group, Inc. Analysis

Data as of 2026-06-18 - not real-time

$154.25

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Everus Construction Group posted a record quarter, with revenue climbing 25% year‑over‑year and EBITDA expanding sharply, driven by both its Electrical & Mechanical and Transmission & Distribution segments. The company’s ROE of nearly 39% and operating cash flow above $290 M underscore strong profitability, yet margins remain modest (gross margin ~12%, operating margin ~7.5%). On the price side, the stock trades at $154.25, comfortably above the 20‑day SMA of $149.8 and far above the 200‑day SMA of $107.5, while the MACD line sits bullish over its signal and the RSI hovers at a neutral 54. Volume is increasing, support sits at $135 and resistance near $161, and market sentiment is in an "Extreme Greed" zone, all of which fuel short‑term bullish momentum.
However, valuation metrics tell a different story: a DCF‑derived fair value of $117 suggests the market is pricing a ~30% premium, the PE ratio of 35.3 exceeds the industry average of 31.2, and the price‑to‑book sits above 11×. Coupled with a high beta of 2.53 and 30‑day volatility of roughly 49%, the stock carries significant systematic risk. No dividend is paid, limiting income appeal. Investors should weigh the strong growth narrative against the steep valuation and elevated risk profile.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish technical indicators (price above SMA20, bullish MACD)
  • Support level at $135 provides downside cushion
  • High market sentiment (Extreme Greed) may fuel short‑term buying

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Revenue growth of 25% and strong ROE suggest continued earnings expansion
  • Valuation premium (price > DCF fair value) limits upside
  • Elevated beta and volatility increase risk

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Overvalued relative to fundamentals (PE 35 vs industry 31, DCF gap)
  • High beta (2.5) and 30‑day volatility (~49%) imply price swings
  • No dividend and modest margins reduce defensive appeal

Key Metrics & Analysis

Financial Health

Revenue Growth25.40%
Profit Margin5.65%
P/E Ratio35.3
ROE38.95%
ROA11.37%
Debt/Equity52.78
P/B Ratio11.5
Op. Cash Flow$293.4M
Free Cash Flow$167.1M
Industry P/E31.2

Technical Analysis

TrendBullish
RSI54.7
Support$135.08
Resistance$160.95
MA 20$149.77
MA 50$146.25
MA 200$107.53
MACDBullish
VolumeIncreasing
Fear & Greed Index90.88

Valuation

Fair Value$117.29
Target Price$169.60
Upside/Downside9.95%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.53
Volatility49.10%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.